Abbott Misses on Diagnostics Revenue, Pressuring Medtech Sentiment and Shifting Focus to Labs and Tools

What happened

Abbott ($ABT) missed quarterly revenue expectations, with weakness highlighted in its diagnostics business. The guidance tone also pressured sentiment across medtech and diagnostics as investors reassess near-term testing demand and pricing.

Why the market cares

When a mega-cap healthcare name misses on diagnostics, traders treat it as a read-through on:

1. diagnostic testing volumes (flu season strength, routine lab utilisation)

2. pricing and mix (COVID-related headwinds fading, but not always cleanly)

3. 2026 guidance credibility across medtech and life-sciences tools

Winners

Reference labs and lab outsourcing

If hospitals and clinics keep tighteni ...